Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsFindings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.
Here's some of what is coming soon to NeurologyLive® this week.
Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.
FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.
5 Pulmonology Headlines You Missed in November 2025
Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43
Stage 5 CKD May Reverse Female Survival Advantage
1.
Research identifies nearly 200 potential breast carcinogens in food packaging materials
2.
Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer
3.
Oncology Drug Shortages Persist, but Continue to Evolve
4.
In a recent study, Kencur ginger's anti-cancer properties were discovered.
5.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
1.
Unlocking the Benefits of Eltrombopag: A Comprehensive Guide
2.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
3.
Gender-Specific Dual Antiplatelet Therapy Strategies for Women After PCI
4.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
5.
Hemophilia: Pathophysiology, Genetics, and Treatment Advances
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Thromboprophylaxis In Medical Settings
2.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
3.
Navigating the Complexities of Ph Negative ALL - Part IX
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge